The purpose of this study is to explore the effects of two iTBS protocols: the compressed iTBS protocol, which is commonly used to treat depression, and the spaced iTBS protocol. We want to see which one is better able to produce changes in brain plasticity and improve depressive symptoms among individuals diagnosed with Major Depressive Disorder. If we are better able to modify brain plasticity using this improved iTBS protocol, it could lead to improved efficacy of iTBS to treat depression.
Eligibility Criteria
Individuals with a diagnosis of Mild Cognitive Impairment
- Age range: Age 18 or above, and less than 51
- Must meet criteria for a current Major Depressive Episode (MDE) determined through a clinical interview;
- Mus score greater than 7 on a standard depression rating scale (HRSD-17);
- Must be on a stable antidepressant regimen for a minimum of 4 weeks prior to enrollment, if currently taking antidepressants;
- Right-handed or ambidextrous;
- You must speak and understand English well enough to complete the study assessments;
- Able to provide informed consent and follow all study procedures.
What does the study involve?
- Number of contacts: 7-9 in-person visits
- Compensation offered? Yes
Investigator(s): Dr. Christoph Zrenner
Full Study Title: Optimization of Prefrontal Theta-Burst Stimulation to Treat Depression: A Bench to First-in-Human Study (INSPiRE-D)
Contact Information:
E-mail: INSPiRE@camh.ca
REB number: 2024/116
REB Approval Expiry Date: October, 2025
PLEASE NOTE:
- Research staff cannot give medical advice over the phone or via email.
- If you have specific questions regarding your health care, please contact your family physician.
- We regret that not everyone screened for a study will be eligible to participate
- For more information about other treatment options for mental illness or addiction offered by CAMH, visit www.camh.ca or call 416-535-8501.